Lovenox Dosing Comparison for Blood Clot Prevention
This study is comparing two different ways of giving enoxaparin (Lovenox), a medicine used to prevent blood clots. You might be eligible if you are an admitted patient over 15 years old, needing Lovenox for trauma or surgery. The study aims to see if giving 30 mg of Lovenox twice a day is better or worse than 40 mg once a day at preventing blood clots (thromboembolic events) and if one dose causes more bleeding. Researchers will check for blood clots daily for up to 90 days. The study's current status is unclear, and it plans to enroll 606 patients.
- Study design
- This is a prospective, randomized study at a single center, comparing two different doses of enoxaparin. It plans to enroll 606 participants.
- What's involved
- You would be randomized to receive either 30 mg of enoxaparin twice daily or 40 mg once daily. You would also undergo weekly ultrasound duplex examinations of your lower extremities.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure thromboembolic events daily, up to 90 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Martin A Schreiber, MD · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Thromboembolic eventsDaily, up to Day 90
Daily monitoring per standard of care for the development of thromboembolic events.